Compare Jabil Inc (JBL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Zimmer Biomet Holdings Inc — how do they compare? Jabil Inc trades at $319.94 (market cap $32.06B), while Zimmer Biomet Holdings Inc trades at $89.57 (market cap $17.36B). The key difference: Jabil Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| JBL | ZBH | |
|---|---|---|
Market Cap | $32.06B | $17.36B |
Sector | Technology | Health |
52-Week High | $385.50 | $107.71 |
52-Week Low | $192.49 | $79.58 |
Enterprise Value | $34.59B | $24.40B |
Dividend Yield | 0.1% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $305.91, up 1.63% today but down significantly from recent highs, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamental performance with consistent earnings beats, 20.62% ROE, and robust revenue growth projections to $33.6B for 2026. Recent developments include expansion of AI infrastructure capabilities and new logistics facilities.
JBL presents a compelling growth story driven by AI infrastructure demand, with analysts maintaining strong buy ratings and a $448.29 consensus target representing 46% upside. However, elevated P/E ratio of 37.67 and competitive pressures in electronics manufacturing warrant caution. The stock's recent pullback may offer entry opportunity for long-term investors bullish on AI-driven growth.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
